Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18447676 | 0.82 | KIT (0.42) | MAPTSMN1; SMN2ALDH1A1ERCC1FEN1 | |
| SCHEMBL10884744 | 0.77 | LPO (0.42) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL12400712 | 0.76 | ERCC1 (0.45) | MAPTSMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL27949444 | 0.74 | LMNA (0.46) | LMNAKMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL2711470 | 0.73 | ERCC1 (0.46) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL8607417 | 0.72 | DRD2 (0.42) | MAPTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1126744 | 0.72 | ALDH1A1 (0.45) | MAPTSMN1; SMN2LMNAGAAHTT | |
| SCHEMBL11024545 | 0.72 | LMNA (0.61) | SMN1; SMN2LMNAKMT2AKDM4EASAH1 | |
| SCHEMBL11452315 | 0.72 | TK2 (0.44) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL10896870 | 0.71 | KDM4E (0.50) | MAPTSMN1; SMN2LMNAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844342-B2 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| EP-1343499-A4 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | YU KUO-LONG (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1343499-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002062290-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | MAPT 4716/4885SMN1; SMN2 516/4885LMNA 2414/4885 |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | MAPT 4716/4885SMN1; SMN2 516/4885LMNA 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.